

**Date: August 10, 2021**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited (NSE),</b> Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
<b>Symbol – LINCOLN</b>	<b>Scrip Code – 531633</b>

Dear Sir,

**SUB.: OUTCOME OF BOARD MEETING.**

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.


Meeting of the Board of Directors commenced at 11:00 a.m. and concluded at 12:30 p.m.

Kindly take the same on your records.

Thanking you,

Yours faithfully,  
**For Lincoln Pharmaceuticals Limited**

*H.A. Desai*  
**Niren A. Desai**  
**Company Secretary**



Encl: A/a

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com


## Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2021.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30/06/2021	31/03/2021	30/06/2020	Year Ended
		(Un-Audited)	Refer No. 4	(Un-Audited)	31/03/2021
<b>1</b>	<b>Income</b>				
	A) Revenue From Operations	11,973.75	7,754.05	10,103.27	41,305.50
	B) Other Income	232.14	250.72	197.49	676.62
	<b>Total Income (1)</b>	<b>12,205.88</b>	<b>8,004.77</b>	<b>10,300.76</b>	<b>41,982.12</b>
<b>2</b>	<b>Expenses</b>				
	A) Cost of Material Consumed	3,061.18	1,880.97	2,010.38	9,550.34
	B) Purchase of Stock-In-Trade	2,460.74	1,272.37	2,673.37	10,400.21
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	331.81	(535.34)	539.89	134.77
	D) Employee Benefits Expenses	1,575.92	1,898.07	1,206.77	5,646.82
	E) Finance Costs	37.52	53.36	33.66	143.79
	F) Depreciation and Amortisation Expense	143.96	141.79	140.55	566.59
	G) Other Expenses	2,145.29	1,814.58	1,628.81	7,438.37
	<b>Total Expenses (2)</b>	<b>9,756.42</b>	<b>6,525.81</b>	<b>8,233.43</b>	<b>33,880.88</b>
<b>3</b>	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>2,449.46</b>	<b>1,478.96</b>	<b>2,067.33</b>	<b>8,101.24</b>
<b>4</b>	Exceptional Items	Nil	Nil	Nil	Nil
<b>5</b>	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>2,449.46</b>	<b>1,478.96</b>	<b>2,067.33</b>	<b>8,101.24</b>
<b>6</b>	Tax Expense				
	A) Current Tax	692.00	320.13	536.00	2,022.13
	B) Deferred Tax	19.66	(8.28)	32.25	56.33
	C) Short / (Excess) Tax Provision	Nil	(17.83)	Nil	(17.83)
<b>7</b>	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>1,737.80</b>	<b>1,184.94</b>	<b>1,499.08</b>	<b>6,040.61</b>
<b>8</b>	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	1.30	38.16	(10.99)	5.21
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
<b>9</b>	<b>Total Comprehensive Income</b>	<b>1,739.10</b>	<b>1,223.10</b>	<b>1,488.10</b>	<b>6,045.82</b>
<b>10</b>	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00
<b>11</b>	Other Equity				34,495.31
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>				
	(a) Basic	8.69	5.92	7.50	30.20
	(b) Diluted	8.69	5.92	7.50	30.20

### NOTES:

- The above standalone financial results of the Company for the quarter ended June 30, 2021 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Tuesday, August 10, 2021. The auditor have carried out an limited review of the said financial results.
- The impact of CoVID-19 may be different from what is estimated as at such date of approval of the financial results and the Company will continue to monitor any material changes to future economic conditions. As the situation is unprecedented, the Company is closely monitoring the situation as it evolves in the future.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2021 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



Place: Ahmedabad  
Date: August 10, 2021

Mahendra G. Patel  
Managing Director  
DIN: 00104706

# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

**Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To the Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**  
Ahmedabad

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended June 30, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


The Statement includes the results for the quarter ended 31st March 2021 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2021 and the unaudited year-to-date figures upto 31st December 2020 which were subjected to a limited review.

**2. Management's Responsibility for the statement:**

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

**3. Auditor's Responsibility:**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

#### 4. Conclusion:

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 10/08/2021



For, J. T. Shah & Co.

Chartered Accountants

(Firm Regd. No: 109616W)

(J. J. Shah)

Partner

(M.No.45669)

UDIN: 21045669AAAADP8741

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com


## Statement of Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2021.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30/06/2021	31/03/2021	30/06/2020	Year Ended
		(Un-Audited)	Refer No. 4	(Un-Audited)	31/03/2021
<b>1</b>	<b>Income</b>				
	A) Revenue From Operations	12,218.87	7,958.04	10,379.36	42,418.54
	B) Other Income	201.08	253.49	179.79	566.39
	<b>Total Income (1)</b>	<b>12,419.95</b>	<b>8,211.53</b>	<b>10,559.16</b>	<b>42,984.93</b>
<b>2</b>	<b>Expenses</b>				
	A) Cost of Material Consumed	3,804.84	2,501.19	2,702.30	12,343.24
	B) Purchase of Stock-In-Trade	1,673.79	510.16	1,680.21	7,031.43
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	256.45	(507.97)	717.15	399.07
	D) Employee Benefits Expenses	1,697.79	2,039.38	1,292.06	6,073.79
	E) Finance Costs	37.55	57.47	67.39	156.17
	F) Deprecation and Amortisation Expense	191.67	189.16	187.82	756.02
	G) Other Expenses	2,254.67	1,890.85	1,770.80	7,853.12
	<b>Total Expenses (2)</b>	<b>9,916.77</b>	<b>6,680.24</b>	<b>8,417.72</b>	<b>34,612.84</b>
<b>3</b>	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>2,503.18</b>	<b>1,531.28</b>	<b>2,141.43</b>	<b>8,372.09</b>
<b>4</b>	Exceptional Items	Nil	Nil	Nil	Nil
<b>5</b>	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>2,503.18</b>	<b>1,531.28</b>	<b>2,141.43</b>	<b>8,372.09</b>
<b>6</b>	Tax Expense				
	A) Current Tax	717.30	325.46	583.76	2129.04
	B) Deferred Tax	15.61	(35.70)	31.56	24.72
	C) Short / (Excess) Tax Provision	Nil	(16.82)	Nil	(6.69)
<b>7</b>	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>1,770.27</b>	<b>1,258.34</b>	<b>1,526.12</b>	<b>6,225.02</b>
<b>8</b>	Attributable to Non-Controlling Interest	0.45	1.05	0.37	2.61
	<b>Attributable to Owners of the Company</b>	<b>1,769.82</b>	<b>1,257.30</b>	<b>1,525.74</b>	<b>6,222.41</b>
<b>9</b>	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	0.48	36.56	(11.55)	1.91
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
<b>10</b>	<b>Total Comprehensive Income</b>	<b>1,770.75</b>	<b>1,294.90</b>	<b>1,514.57</b>	<b>6,226.93</b>
<b>11</b>	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00
<b>12</b>	Other Equity				35,529.21
<b>13</b>	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>				
	(a) Basic	8.85	6.29	7.63	31.11
	(b) Diluted	8.85	6.29	7.63	31.11

### NOTES:

- The above consolidated financial results of the Company for the quarter ended June 30, 2021 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Tuesday, August 10, 2021. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the quarter ended March 31, 2021 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated results includes results of its subsidiaries.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel  
Managing Director  
DIN: 00104706

Place: Ahmedabad  
Date: August 10, 2021

# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

**Limited Review Report on consolidated un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To the Board of Directors of,  
Lincoln Pharmaceuticals Limited,  
Ahmedabad

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Lincoln Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Statement includes the results for the quarter ended 31st March 21 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2021 and the unaudited year-to-date figures upto 31st December 2020 which were subjected to a limited review.


2. **Management's Responsibility for the statement:**

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. **Auditor's Responsibility:**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

**4. The Statement includes the results of the following entities:**

- |                                    |   |                                 |
|------------------------------------|---|---------------------------------|
| A. Lincoln Pharmaceuticals Limited | - | Parent Company                  |
| B. Lincoln Parenteral Limited      | - | Subsidiary Company              |
| C. Zullinc Healthcare LLP          | - | Wholly-Owned Subsidiary Company |

**5. Conclusion:**

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**6. Other Matter:**

We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflects total revenues of Rs. Nil Lacs, total net loss after tax of Rs.0.95 Lacs, for the quarter ended June 30, 2021, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

According to the information and explanations given to us by the Management, above financial results are not material to the Group. Our conclusion on the Statement, in so far as it relates to the amounts included in respect of these subsidiaries, is based solely on the information and explanations given to us by the Management.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

**Place: Ahmedabad**

**Date: 10/08/2021**



**For, J.T. Shah & Co.  
Chartered Accountants  
(Firm Regd. No: 109616W)**

**(J. J. Shah)**

**Partner**

**(M.No.45669)**

**UDIN: 21045669AAAADQ8534**

**Media Release**

**Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of ₹ 17.38 crore in Q1FY22, growth of 15.92% Y-o-Y**

**Financial Highlights (Standalone)**

(Amount in Cr except EPS)

	Q1 FY22	Q1 FY21	Y-O-Y	FY21	FY20	Y-O-Y
Net Revenue from Operations	122.06	103.01	18.49%	419.82	388.21	8.14%
EBITDA	26.31	22.42	17.37%	88.12	71.50	23.24%
<b>Profit before Tax</b>	<b>24.49</b>	<b>20.67</b>	<b>18.48%</b>	<b>81.01</b>	<b>64.05</b>	<b>26.49%</b>
Net Profit	17.38	14.99	15.92%	60.41	49.56	21.88%
<b>E.P.S (Rs.)</b>	<b>8.69</b>	<b>7.50</b>	<b>15.92%</b>	<b>30.20</b>	<b>24.78</b>	<b>21.88%</b>

**Ahmedabad, August 10, 2021:** Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has reported a standalone net profit of ₹ 17.38 crore for the Q1FY22 ended June 2021 as against net profit of ₹ 14.99 crore in the corresponding period last year, growth of 15.92%. Net revenue from operations in Q1FY22 was reported at ₹ 122.06 crore, higher by 18.49% over previous fiscal's same quarter net revenue of ₹ 103.01 crore.

EBITDA for Q1FY22 was reported at ₹ 26.31 crore, rise of 17.37% as compared to EBITDA of ₹ 22.42 crore in Q1FY21. In Q1FY22, EPS for Q1FY22 was at ₹ 8.69 per share as compared to ₹ 7.50 in the corresponding period last year.

Commenting on the results and performance, **Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said,** "We are confident to improve our growth numbers of revenue, margins and profitability in FY22. Our strategic growth initiatives, product and geographical expansion, operational efficiency and debt free status are likely to maximise value for all stakeholders in the near to medium term. For the FY 21-22 company is looking at a sales growth of 15-20% while maintaining healthy EBITA and Net profit margins. Expanding the product basket, company plans to introduce 6 – 7 new products in the domestic markets and expects 20 – 25 new dossiers approval for the exports market. Exports to EU markets are likely to commence from Q4FY22."

Over the last 5 years, company has delivered a robust 20% plus CAGR in profits and higher single digit growth in sales. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no term debt and healthy return ratios. Backed by improvement in the company's financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company's long-term and short-term bank facilities to A and A1 respectively.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288  
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.  
Ta. : Kalol, Dist. Gandhinagar, (Guj.) | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com





During Q1FY22 ended June 2021, promoter group of Lincoln Pharmaceuticals Ltd increased holding in the company to 37.78% - rise of 52 bps, from 37.26% as of March 31, 2021. Promoter group bought 1.04 lakh shares from the secondary market during the quarter. During FY21 also promoter group through creeping acquisition raised stake in the company to 37.26% - rise of 500 bps, from 32.36% in FY20.

Exports for Q1FY22 was reported at ₹ 69.76 crore. Export business of the company has shown remarkable growth in the last few years and had increased to 65% of total sales in FY21 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. For the FY21, exports grew 18.4% to ₹ 270 crore.

Company is witnessing good traction in the export business, which is expected to get further boost once EU operations begins. Company is building a strong portfolio in lifestyle and chronic segments especially dermatology, gastro and pain management to complement its strong presence in the acute segment.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

\*\*\*

**About Lincoln Pharmaceuticals Limited:** <https://www.lincolnpharma.com/>

Providing Affordable and Innovative medicines for healthier lives.


Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288  
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, [Guj.] | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

**For further information please contact:**

**Gopal Modi / Rupesh Panchal**  
ColdCoco Consultancy, Ahmedabad  
9099030184 / 9925023103  
gopal@coldcococonsultancy.com  
rupesh@coldcococonsultancy.com

**Darshit A. Shah (Chief Financial Officer)**  
Lincoln Pharmaceuticals Limited, Ahmedabad  
+91-79-4107-8048  
darshit@lincolnpharma.com

